INIS (Radnostix) Total Liabilities: $14.54 Mil (As of Mar. 2026)


What is Radnostix Total Liabilities?

Radnostix INIS -28.29% Total Liabilities is $14.54 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Radnostix's Total Liabilities for the quarter that ended in Mar. 2026 was $14.54 Mil.

Radnostix's quarterly Total Liabilities increased from Sep. 2025 ($13.75 Mil) to Dec. 2025 ($14.14 Mil) and increased from Dec. 2025 ($14.14 Mil) to Mar. 2026 ($14.54 Mil).

Radnostix's annual Total Liabilities declined from Dec. 2023 ($12.87 Mil) to Dec. 2024 ($12.81 Mil) but then increased from Dec. 2024 ($12.81 Mil) to Dec. 2025 ($14.14 Mil).

Radnostix Total Liabilities Historical Data

* Premium members only.

The historical data trend for Radnostix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radnostix Total Liabilities Chart

Radnostix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.60 11.90 12.87 12.81 14.14

Radnostix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.23 13.24 13.75 14.14 14.54

Radnostix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Radnostix's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.974+(4.488+5.682
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.14

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=17.837-3.693
=14.14

Radnostix's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.447+(4.394+5.701
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.54

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=17.188-2.646
=14.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $14.54 Mil mean?
Radnostix (INIS) has a Total Liabilities of $14.54 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Radnostix and its competitors.
Is Radnostix's Total Liabilities too high?
Radnostix's current Total Liabilities is $14.54 Mil.
How does Radnostix's Total Liabilities compare to SCYX and BTAI?
Radnostix's Total Liabilities of $14.54 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Radnostix and its competitors. Radnostix's current Total Liabilities is $14.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.05 — trading 2.4% above its estimated fair value. The current Total Liabilities is $14.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Radnostix (INIS), the current Total Liabilities is $14.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radnostix Business Description

Address 4137 Commerce Circle, Idaho Falls, ID, USA, 83401
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.